Ascendis Pharma AS Market Cap ($12.65 Billion)
Market Cap & Net Worth: Ascendis Pharma AS (A71)
Ascendis Pharma AS market cap. Ascendis Pharma AS (F:A71) has a market capitalization of $12.65 Billion (€10.82 Billion) as of November 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #1800 globally and #388 in its home market, demonstrating a 4.04% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ascendis Pharma AS's stock price €206.00 by its total outstanding shares 61393156 (61.39 Million). Also see A71 operating cash flow for how efficiently the company converts equity into cash flow.
Ascendis Pharma AS Market Cap History (2026–2026)
Ascendis Pharma AS market cap history from 2026 to 2026. Data shows growth from $14.79 Billion to $14.79 Billion (0.00% CAGR). Check A71 stock price for real-time trading data and today's change.
Ascendis Pharma AS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ascendis Pharma AS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore A71 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of A71 by Market Capitalization
Companies near Ascendis Pharma AS in the global market cap rankings as of November 1, 2026. Also see Ascendis Pharma AS total assets for a full breakdown of the balance sheet.
Key companies related to Ascendis Pharma AS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Ascendis Pharma AS (2026–2026)
Market capitalization of Ascendis Pharma AS from 2026 to today. Between 2026 and today, Ascendis Pharma AS's market cap moved from $14.79 Billion to $ 14.79 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €14.79 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Ascendis Pharma AS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.65 Billion USD |
| MoneyControl | $12.65 Billion USD |
| MarketWatch | $12.65 Billion USD |
| marketcap.company | $12.65 Billion USD |
| Reuters | $12.65 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more